Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Joyzyme Group's share price for the quarter that ended in Dec. 2025 was HK$0.435. Joyzyme Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 515.47 Mil. Therefore, Joyzyme Group's market cap for the quarter that ended in Dec. 2025 was HK$224.23 Mil.
Joyzyme Group's quarterly market cap
increased
from Dec. 2024 (HK$75.07 Mil) to Jun. 2025 (HK$197.69 Mil) and
increased
from Jun. 2025 (HK$197.69 Mil) to Dec. 2025 (HK$224.23 Mil).
Joyzyme Group's annual market cap
increased
from Dec. 2023 (HK$44.78 Mil) to Dec. 2024 (HK$75.07 Mil) and
increased
from Dec. 2024 (HK$75.07 Mil) to Dec. 2025 (HK$224.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Joyzyme Group's Enterprise Value for Today is HK$39.37 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Joyzyme Group Market Cap Related Terms
Joyzyme Group Market Cap Historical Data
* Premium members only.
The historical data trend for Joyzyme Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Joyzyme Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joyzyme Group Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Joyzyme Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Joyzyme Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Joyzyme Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joyzyme Group (HKSE:08622) has a Market Cap of HK$85.05 Mil as of Aug. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Joyzyme Group and its competitors. According to the industry distribution chart, Joyzyme Group ranks #870 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 85.1%.
Is Joyzyme Group's Market Cap too high?
Joyzyme Group's current Market Cap is HK$85.05 Mil. Based on the distribution chart, Joyzyme Group ranks #870 out of 1022 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Joyzyme Group has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Joyzyme Group's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joyzyme Group ranks #870 out of 1022 companies for Market Cap. This places Joyzyme Group in the lower half of its industry. The industry median Market Cap is 232.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 232.89, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Joyzyme Group and its competitors. For the Drug Manufacturers industry, the median Market Cap is 232.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joyzyme Group's current Market Cap is HK$85.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joyzyme Group stock overvalued right now?
Based on GuruFocus' analysis, Joyzyme Group (HKSE:08622) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.17, compared to a current price of HK$0.17 — trading 2.9% below its estimated fair value. The current Market Cap is HK$85.05 Mil. Joyzyme Group's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Joyzyme Group (HKSE:08622), the current Market Cap is HK$85.05 Mil as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joyzyme Group (HKSE:08622) Overvalued in 2026?
Based on GuruFocus' analysis, Joyzyme Group stock appears to be undervalued.
The current stock price of HK$0.17 is trading 2.9% below its estimated GF Value™ of HK$0.17.
GuruFocus considers Joyzyme Group to be Fairly Valued.
Key valuation signals for HKSE:08622:
Market Cap: HK$85.05 Mil
GF Value™: HK$0.17 vs. price of HK$0.17 (2.9% below fair value)
No single metric tells the full story. See the HKSE:08622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo.16 Yinkui Road, 1-3 floor and 5th floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Joyzyme Group Ltd is an investment holding company. The Company and its subsidiaries are principally engaged in research and development, manufacture, marketing, and sale of biological reagents and auxiliary reproductive supplies and equipment, and healthcare products and supplements in the People's Republic of China (the PRC). It operates in two segments: Biological reagents and auxiliary reproductive supplies and equipment, and Healthcare products and supplements. It generates the majority of its revenue from the biological reagents and auxiliary reproductive supplies and equipment segment. Geographically, it generates revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:08622
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08622 has been successfully added to your 
